CBIO
Crescent Biopharma, Inc. (NASDAQ)
Healthcare — Biotechnology
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Price History
Fundamentals
| Market Cap | $470.98M |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.80 |
| EPS (TTM) | $-5.88 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 0.84 |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $31.00 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 46.1 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $27.41 |
| 52-Week Low | $8.72 |
| 50-Day Avg | $19.49 |
| 200-Day Avg | $14.47 |
| Avg Volume | 355.8K |
| Volume | 323.9K |
Performance Analysis
BULLISHCBIO shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:02 UTC
Back to Screener Export Report